He Tao, Mohammadpour Behnood, Willman Matthew, Yaghoobpoor Shirin, Willman Jonathan, Lucke-Wold Brandon, Aminizadeh Sarina, Khanzadeh Shokoufeh, Bazrgar Aida, Ghaedi Arshin
The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou City, China.
Department of Medicine, Islamic Azad University of Medical Sciences, Tonekabon Campus, Tonekabon, Iran.
Angiology. 2024 Mar 15:33197241238512. doi: 10.1177/00033197241238512.
This meta-analysis assessed the use of the neutrophil-to-lymphocyte ratio (NLR) as a means of early detection of contrast-induced nephropathy (CIN) following diagnostic or therapeutic procedures. We used Web of Science, PubMed, and Scopus to conduct a systematic search. There was no limitation regarding language or date of publication. We reported standardized mean difference (SMD) with a 95% confidence interval (CI). Due to high heterogeneity, a random-effects model was used, and the Newcastle-Ottawa scale was used for quality assessment. Thirty-one articles were included in the analysis. Patients in the CIN group had elevated levels of NLR compared with those in the non-CIN group (SMD = 0.78, 95% CI = 0.52-1.04, < .001). Similar results were observed in either prospective (SMD = 1.03, 95% CI = 0.13-1.93, = .02) or retrospective studies (SMD = 0.70, 95% CI = 0.45-0.96, < .001). The pooled sensitivity of NLR was 74.02% (95% CI = 66.54%-81.02%), and the pooled specificity was 60.58% (95% CI = 53.94%-66.84%). NLR shows potential as a cost-effective biomarker for predicting CIN associated with contrast-involved treatments. This could help implement timely interventions to mitigate CIN and improve outcomes.
本荟萃分析评估了中性粒细胞与淋巴细胞比值（NLR）作为诊断或治疗性操作后对比剂肾病（CIN）早期检测手段的应用。我们使用科学网、PubMed和Scopus进行系统检索。对语言或出版日期没有限制。我们报告了标准化均数差（SMD）及其95%置信区间（CI）。由于异质性高，采用随机效应模型，并使用纽卡斯尔-渥太华量表进行质量评估。31篇文章纳入分析。与非CIN组相比，CIN组患者的NLR水平升高（SMD = 0.78，95%CI = 0.52 - 1.04，P <.001）。前瞻性研究（SMD = 1.03，95%CI = 0.13 - 1.93，P =.02）或回顾性研究（SMD = 0.70，95%CI = 0.45 - 0.96，P <.001）中均观察到类似结果。NLR的合并敏感度为74.02%（95%CI = 66.54% - 81.02%），合并特异度为60.58%（95%CI = 53.94% - 66.84%）。NLR显示出作为预测与含对比剂治疗相关CIN的经济有效生物标志物的潜力。这有助于实施及时干预以减轻CIN并改善结局。
